CVS Health Corporation’s stock price surges to $62.88, marking a robust 2.44% increase

CVS Health Corporation (CVS)

62.88 USD +1.50 (+2.44%) Volume: 15.93M

CVS Health Corporation’s stock price surged to 62.88 USD, marking a positive trading session with a 2.44% increase on a volume of 15.93M shares, despite a year-to-date decrease of 20.36%, reflecting the dynamic performance of CVS in the stock market.

Latest developments on CVS Health Corporation

Today, CVS Health Corp’s stock price movements are influenced by activist investor Glenview Capital pushing for operational improvements. The health care giant is set to slash thousands of jobs, with some likely in Connecticut. Glenview is meeting with top CVS executives to propose strategic changes amid struggles faced by the company. As a result, CVS Health shares are on the rise as investors anticipate potential changes following the high-level talks. The company’s stock price has climbed in anticipation of the meeting, reflecting investor optimism for the proposed operational improvements.

CVS Health Corporation on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely monitoring the coverage of Cvs Health Corp. In their report titled “CVS Health Corporation: Strategic Leverage in Pharmacy Benefit Management (PBM) and Insurance Operations! – Major Drivers,” the analysts highlighted the company’s mixed financial results in the second quarter of 2024. Despite facing notable challenges, CVS Health reported adjusted earnings per share of $1.83 and revenues exceeding $91 billion, supported by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

Another report by Baptista Research on Smartkarma, titled “CVS Health Corporation: Will The Increasing Margin in Medicare Advantage Last? – Major Drivers,” discussed the positive and negative impacts on CVS Health’s business structure in Q1 2024. The company reported lower-than-expected earnings per share of $1.31, attributing it to significant utilization pressures in the Medicare Advantage segment. As a result, CVS Health has revised its full-year guidance for adjusted EPS to at least $7, reflecting the challenges and adjustments in the healthcare landscape.

A look at CVS Health Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, CVS Health Corp is rated highly for its value and dividend, scoring a 5 out of 5 in both categories. This indicates a positive long-term outlook for the company in terms of its financial stability and ability to provide returns to shareholders. While the growth and resilience scores are slightly lower at 3, CVS Health Corp still maintains a solid momentum score of 4. Overall, the company’s integrated pharmacy health care services and nationwide presence position it well for continued success in the future.

CVS Health Corporation is an integrated pharmacy health care provider with a strong focus on pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. With a top rating in value and dividend, as well as solid scores in growth, resilience, and momentum, CVS Health Corp demonstrates its commitment to providing quality healthcare services while also delivering value to its investors. As the company continues to expand its presence across the U.S., the District of Columbia, and Puerto Rico, it is poised for sustained growth and success in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma